| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Torch Panel IgG
MessageSendout, Mayo test code: TRCHG
Test Code
LAB5210717
Alias/See Also
Rubella
Toxoplasma
Cytomegalovirus (CMV)
Herpes Simplex Virus (HSV)
TRCHG
Toxoplasma
Cytomegalovirus (CMV)
Herpes Simplex Virus (HSV)
TRCHG
CPT Codes
86644, 86695, 86696, 86762, 86777
Preferred Specimen
2 mL serum from a gold serum gel tube
Minimum Volume
1.2 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 14 days
Frozen 14 days
Frozen 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Heat-inactivated specimen: Reject
Gross lipemia: Reject
Gross icterus: Reject
Heat-inactivated specimen: Reject
Methodology
Multiplex Flow Immunoassay (MFI)
FDA Status
Approved
Setup Schedule
Monday through Saturday
Report Available
1-3 days
Limitations
Toxoplasma gondii:
Sera collected very early during the acute stage of infection may have Toxoplasma IgG levels less than 9 IU/mL.
The Toxoplasma IgG assay should not be used alone to diagnose recent T gondii infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings.
The performance characteristics of this assay have not been evaluated in immunocompromised individuals and have not been established for cord blood or for testing of neonates.
Rubella:
Specimens collected early during the acute phase of infection or shortly (1-2 weeks) following vaccination may be negative for IgG class antibodies.
Cytomegalovirus:
Sera collected very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgG.
The CMV IgG assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected diseases, submit a second specimen for testing in 10 to 14 days.
The performance characteristics of this assay have not been evaluated in immunosuppressed or organ transplant recipients and have not been established for cord blood or for testing of neonates.
Immune complexes or other immunoglobulin aggregates present in patient specimen may cause increased nonspecific binding and produce false-positive results.
Potential cross-reactivity for CMV with human chorionic gonadotropin, HIV IgG, multiple myeloma IgG, rheumatoid factor IgM, and T gondii IgG have not be ruled out.
Herpes Simplex Virus Types 1 and 2:
Detection of IgG-class antibodies to herpes simplex virus (HSV) should not be used routinely as the primary means of diagnosing HSV infection. For patients presenting with presumed acute infection with HSV, a clinical specimen (eg, oral, dermal, or genital lesion) should be sampled and submitted for detection of HSV types 1 and 2 by rapid polymerase chain reaction (PCR) (HERPB / Herpes Simplex Virus 1 and 2, Qualitative PCR, Blood).
Serum specimens collected too early in the course of infection may not have detectable levels of HSV IgG. In cases of suspected early disease, a repeat serum specimen should be collected 14 to 21 days later and submitted for testing.
The presence of IgG-class antibodies to either HSV type 1 or 2 does not differentiate between remote infection and acute disease.
HSV serology cannot distinguish genital from nongenital infections.
The predictive value of positive or negative results depends on the prevalence of disease and the pretest likelihood of HSV type 1 and HSV type 2. False-positive results may occur. Repeat testing, or testing by a different method, may be indicated in some settings (eg, patients with low likelihood of HSV infection).
Sera collected very early during the acute stage of infection may have Toxoplasma IgG levels less than 9 IU/mL.
The Toxoplasma IgG assay should not be used alone to diagnose recent T gondii infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings.
The performance characteristics of this assay have not been evaluated in immunocompromised individuals and have not been established for cord blood or for testing of neonates.
Rubella:
Specimens collected early during the acute phase of infection or shortly (1-2 weeks) following vaccination may be negative for IgG class antibodies.
Cytomegalovirus:
Sera collected very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgG.
The CMV IgG assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected diseases, submit a second specimen for testing in 10 to 14 days.
The performance characteristics of this assay have not been evaluated in immunosuppressed or organ transplant recipients and have not been established for cord blood or for testing of neonates.
Immune complexes or other immunoglobulin aggregates present in patient specimen may cause increased nonspecific binding and produce false-positive results.
Potential cross-reactivity for CMV with human chorionic gonadotropin, HIV IgG, multiple myeloma IgG, rheumatoid factor IgM, and T gondii IgG have not be ruled out.
Herpes Simplex Virus Types 1 and 2:
Detection of IgG-class antibodies to herpes simplex virus (HSV) should not be used routinely as the primary means of diagnosing HSV infection. For patients presenting with presumed acute infection with HSV, a clinical specimen (eg, oral, dermal, or genital lesion) should be sampled and submitted for detection of HSV types 1 and 2 by rapid polymerase chain reaction (PCR) (HERPB / Herpes Simplex Virus 1 and 2, Qualitative PCR, Blood).
Serum specimens collected too early in the course of infection may not have detectable levels of HSV IgG. In cases of suspected early disease, a repeat serum specimen should be collected 14 to 21 days later and submitted for testing.
The presence of IgG-class antibodies to either HSV type 1 or 2 does not differentiate between remote infection and acute disease.
HSV serology cannot distinguish genital from nongenital infections.
The predictive value of positive or negative results depends on the prevalence of disease and the pretest likelihood of HSV type 1 and HSV type 2. False-positive results may occur. Repeat testing, or testing by a different method, may be indicated in some settings (eg, patients with low likelihood of HSV infection).
Reference Range
Included with report
Clinical Significance
Determining immune status of individuals to the rubella virus following vaccination or prior exposure
Indicating past or recent infection with Toxoplasma gondii, cytomegalovirus, or herpes simplex virus (HSV)
Distinguishing between infection caused by HSV types 1 and 2, especially in patients with subclinical or unrecognized HSV infection
Indicating past or recent infection with Toxoplasma gondii, cytomegalovirus, or herpes simplex virus (HSV)
Distinguishing between infection caused by HSV types 1 and 2, especially in patients with subclinical or unrecognized HSV infection
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
ToRCH Profile IgG, Serum
